Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Shanghai Henlius' Rituxan Biosimilar is First Biosimilar Approved in China

publication date: Feb 26, 2019

Shanghai Henlius Biotech's biosimilar to Roche's Rituxan has been approved by China’s NMPA, the first biosimilar approved in China. Shanghai Henlius, which was set up in 2010 as a JV between Shanghai Fosun Pharma and US-based Henlius, focuses on novel and biosimilar mAbs. In a China Phase III trial, the Henlius biosimilar showed it matched the efficacy of the Roche original in patients with CD20-positive non-Hodgkin lymphoma. Ironically, Rituxan was the first monoclonal antibody approved for US use as a cancer treatment. More details....

Stock Symbols: (HK: 02196: SHA: 600196)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.